


Express Mail Label No.: EV376271770US

Date of Deposit: September 13, 2005

Attorney Docket No.: 24852-501 CIP4

9-15-05

IFW



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Bacopoulos et al. CONFIRMATION NUMBER: 9840  
SERIAL NUMBER: 10/692,523 EXAMINER: Not Yet Assigned  
FILING DATE: October 24, 2003 ART UNIT: 1614  
FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited References A20-A22 and C84-C85; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.


The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP4. Please address all correspondence to customer number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor Elrifi, Reg. No. 39,529  
Caryn DeHoratius, Reg. No. 45,881  
Attorneys for Applicants  
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*  
666 Third Avenue, 24<sup>th</sup> Floor  
New York, New York 10017  
Phone: (212) 935-3000  
Fax: (212) 983-3115

Dated: September 13, 2005

**EV376271770US**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Bacopoulos et al. CONFIRMATION NUMBER: 9840  
SERIAL NUMBER: 10/692,523 EXAMINER: Not Yet Assigned  
FILING DATE: October 24, 2003 ART UNIT: 1614  
FOR: **METHODS OF TREATING CANCER WITH HDAC INHIBITORS**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed to be required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP4. Please address all correspondence to customer number 35437. A duplicate copy of this transmittal letter is enclosed herewith.


Respectfully submitted,

Dated: September 13, 2005



---

Ivor Elrifi, Reg. No. 39,529  
Caryn DeHoratius, Reg. No. 45,881  
Attorneys for Applicants  
c/o MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY & POPEO P.C.  
Chrysler Center  
666 Third Avenue, 24<sup>th</sup> Floor  
New York, New York 10017  
Phone: (212) 935-3000  
Fax: (212) 983-3115



Express Mail Label No.: EV376271770US  
Date of Deposit: September 13, 2005

PAGE 1 of 1

/ Please type a plus sign (+) in this box ☐

PTO/SB (12-97)  
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |                        |                  |
|---|------------------------|------------------|
| <b>Modified Form 1449/PTO</b><br><br><b>SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) | Application Number     | 10/692,523       |
|   | Filing Date            | 10/24/03         |
|   | First Named Inventor   | Bacopoulos       |
|   | Group Art Unit         | 1614             |
|   | Examiner Name          | Not Yet Assigned |
|   | Attorney Docket Number | 24852-501 CIP4   |

| U.S. PATENT DOCUMENTS |          |                          |            |                                     |       |           |             |
|-----------------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|-------------|
| Exam Initials         | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date |
|                       | A20      | RE38,506 E               | 04/20/04   | Breslow, et al.                     | 514   | 316       | 10/04/1991  |
|                       | A21      | 2003/0082666             | 05/01/03   | Kammer, et al.                      | 435   | 18        | 07/02/2002  |
|                       | A22      | 2003/0235588             | 12/25/03   | Richon, et al.                      | 424   | 146.1     | 02/14/2003  |
|                       |          |                          |            |                                     |       |           |             |

| FOREIGN PATENT DOCUMENTS |          |                                       |                                     |  |                     |                    |  |
|--------------------------|----------|---------------------------------------|-------------------------------------|--|---------------------|--------------------|--|
| Exam Initials            | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) |  | Date of Publication | Translation Yes No |  |
|                          |          |                                       |                                     |  |                     |                    |  |

| NON PATENT LITERATURE DOCUMENTS |          |   |
|---------------------------------|----------|---|
| Exam Initials                   | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.                    |
|                                 | C81      | O'Connor et al. (2001). <i>Journal of the American Society of Hematology</i> 611a, Abstract No. 2562. |
|                                 | C82      | Kelly, et al. (2003). <i>Clinical Cancer Research</i> 9:3578-3588.                                    |
|                                 |          |   |

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**BEST AVAILABLE COPY**